Olix Pharmaceuticals Inc. has obtained promising data with OLX-702-A, an investigational GalNAc-asiRNA therapeutic for the treatment of nonalcoholic steatohepatitis (NASH), in a nonhuman primate NASH model. Administration of OLX-702-A resulted in a significant reduction in liver fat content, measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF).